ELISL: early-late integrated synthetic lethality prediction in cancer.

Abstract excerpt

MOTIVATION: Anti-cancer therapies based on synthetic lethality (SL) exploit tumour vulnerabilities for treatment with reduced side effects, by targeting a gene that is jointly essential with another whose function is lost. Computational prediction is key to expedite SL screening, yet existing methods are vulnerable to prevalent selection bias in SL data and reliant on cancer or tissue type-specific omics, which...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mutation
• Share to Neoplasms
• Share to Synthetic Lethal Mutations